Opinion

Video

Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC

Panelists discuss how, PDS0101 uses Versamune® lipid nanoparticles to deliver HPV16 antigens, activating T-cells. Early Phase 2 data with pembrolizumab showed promise in HPV16+ head & neck cancer patients.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please describe the mechanism of action of the novel Versamune (PDS0101) HPV-16 targeted cancer vaccine.
    • Please discuss the recent data presented for the Phase 2 VERSATILE-002 study of PDS0101 + pembrolizumab in adults with HPV16 and PD-L1 positive recurrent/metastatic HNSCC.
    • Weiss et al. ESMO 2024
    • Versatile-002 - 879P - ESMO 2024

    Related Content